NOX4-driven ROS Formation Mediates PTP Inactivation and Cell Transformation in FLT3ITD-positive AML Cells

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2015 Aug 27

PMID 26308771

Citations 35

Authors

A K Jayavelu

J P Muller

R Bauer

S-A Bohmer

J Lassig

S Cerny-Reiterer

W R Sperr

P Valent

B Maurer

R Moriggl

K Schroder

A M Shah

M Fischer

S Scholl

J Barth

T Oellerich

T Berg

H Serve

S Frey

T Fischer

F H Heidel

F-D Bohmer

Affiliations

Soon will be listed here.

Abstract

Activating mutations of FMS-like tyrosine kinase 3 (FLT3), notably internal tandem duplications (ITDs), are associated with a grave prognosis in acute myeloid leukemia (AML). Transforming FLT3ITD signal transduction causes formation of reactive oxygen species (ROS) and inactivation of the protein-tyrosine phosphatase (PTP) DEP-1/PTPRJ, a negative regulator of FLT3 signaling. Here we addressed the underlying mechanisms and biological consequences. NADPH oxidase 4 (NOX4) messenger RNA and protein expression was found to be elevated in FLT3ITD-positive cells and to depend on FLT3ITD signaling and STAT5-mediated activation of the NOX4 promoter. NOX4 knockdown reduced ROS levels, restored DEP-1 PTP activity and attenuated FLT3ITD-driven transformation. Moreover, Nox4 knockout (Nox4(-/-)) murine hematopoietic progenitor cells were refractory to FLT3ITD-mediated transformation in vitro. Development of a myeloproliferative-like disease (MPD) caused by FLT3ITD-transformed 32D cells in C3H/HeJ mice, and of a leukemia-like disease in mice transplanted with MLL-AF9/ FLT3ITD-transformed murine hematopoietic stem cells were strongly attenuated by NOX4 downregulation. NOX4-targeting compounds were found to counteract proliferation of FLT3ITD-positive AML blasts and MPD development in mice. These findings reveal a previously unrecognized mechanism of oncoprotein-driven PTP oxidation, and suggest that interference with FLT3ITD-STAT5-NOX4-mediated overproduction of ROS and PTP inactivation may have therapeutic potential in a subset of AML.

Citing Articles

Susceptibility of acute myeloid leukemia cells to ferroptosis and evasion strategies.

Zhang H, Sun C, Sun Q, Li Y, Zhou C, Sun C Front Mol Biosci. 2023; 10:1275774.

PMID: 37818101 PMC: 10561097. DOI: 10.3389/fmolb.2023.1275774.

NADPH oxidase mediated oxidative stress signaling in FLT3-ITD acute myeloid leukemia.

Chen Y, Zou Z, Gaman M, Xu L, Li J Cell Death Discov. 2023; 9(1):208.

PMID: 37391442 PMC: 10313758. DOI: 10.1038/s41420-023-01528-5.

STAT proteins in cancer: orchestration of metabolism.

Li Y, Zhang C, Martincuks A, Herrmann A, Yu H Nat Rev Cancer. 2023; 23(3):115-134.

PMID: 36596870 DOI: 10.1038/s41568-022-00537-3.

Disrupting PTPRJ transmembrane-mediated oligomerization counteracts oncogenic receptor tyrosine kinase FLT3 ITD.

Schwarz M, Rizzo S, Paz W, Kresinsky A, Thevenin D, Muller J Front Oncol. 2022; 12:1017947.

PMID: 36452504 PMC: 9701752. DOI: 10.3389/fonc.2022.1017947.

DNA damage and metabolic mechanisms of cancer drug resistance.

Tiek D, Cheng S Cancer Drug Resist. 2022; 5(2):368-379.

PMID: 35800362 PMC: 9255237. DOI: 10.20517/cdr.2021.148.

References

Ostman A, Frijhoff J, Sandin A, Bohmer F . Regulation of protein tyrosine phosphatases by reversible oxidation. J Biochem. 2011; 150(4):345-56. DOI: 10.1093/jb/mvr104. View

Heidel F, Bullinger L, Arreba-Tutusaus P, Wang Z, Gaebel J, Hirt C . The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML. J Exp Med. 2013; 210(1):15-22. PMC: 3549713. DOI: 10.1084/jem.20120596. View

Zhang B, Liu Z, Hu X . Inhibiting cancer metastasis via targeting NAPDH oxidase 4. Biochem Pharmacol. 2013; 86(2):253-66. DOI: 10.1016/j.bcp.2013.05.011. View

Estey E, Dohner H . Acute myeloid leukaemia. Lancet. 2006; 368(9550):1894-907. DOI: 10.1016/S0140-6736(06)69780-8. View

Nishida H, Tatewaki N, Nakajima Y, Magara T, Ko K, Hamamori Y . Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response. Nucleic Acids Res. 2009; 37(17):5678-89. PMC: 2761266. DOI: 10.1093/nar/gkp593. View

Palmqvist L, Argiropoulos B, Pineault N, Abramovich C, Sly L, Krystal G . The Flt3 receptor tyrosine kinase collaborates with NUP98-HOX fusions in acute myeloid leukemia. Blood. 2006; 108(3):1030-6. DOI: 10.1182/blood-2005-12-007005. View

Cui Y, Riedlinger G, Miyoshi K, Tang W, Li C, Deng C . Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol Cell Biol. 2004; 24(18):8037-47. PMC: 515028. DOI: 10.1128/MCB.24.18.8037-8047.2004. View

Xi G, Shen X, Wai C, Clemmons D . Recruitment of Nox4 to a plasma membrane scaffold is required for localized reactive oxygen species generation and sustained Src activation in response to insulin-like growth factor-I. J Biol Chem. 2013; 288(22):15641-53. PMC: 3668724. DOI: 10.1074/jbc.M113.456046. View

Caldarelli A, Muller J, Paskowski-Rogacz M, Herrmann K, Bauer R, Koch S . A genome-wide RNAi screen identifies proteins modulating aberrant FLT3-ITD signaling. Leukemia. 2013; 27(12):2301-10. PMC: 3865536. DOI: 10.1038/leu.2013.83. View

10.

Nisimoto Y, Diebold B, Cosentino-Gomes D, Constentino-Gomes D, Lambeth J . Nox4: a hydrogen peroxide-generating oxygen sensor. Biochemistry. 2014; 53(31):5111-20. PMC: 4131900. DOI: 10.1021/bi500331y. View

11.

Heidel F, Bullinger L, Feng Z, Wang Z, Neff T, Stein L . Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell. 2012; 10(4):412-24. PMC: 3339412. DOI: 10.1016/j.stem.2012.02.017. View

12.

Choudhary C, Schwable J, Brandts C, Tickenbrock L, Sargin B, Kindler T . AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood. 2005; 106(1):265-73. DOI: 10.1182/blood-2004-07-2942. View

13.

Kontro M, Kuusanmaki H, Eldfors S, Burmeister T, Andersson E, Bruserud O . Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia. Leukemia. 2014; 28(8):1738-42. DOI: 10.1038/leu.2014.89. View

14.

Godfrey R, Arora D, Bauer R, Stopp S, Muller J, Heinrich T . Cell transformation by FLT3 ITD in acute myeloid leukemia involves oxidative inactivation of the tumor suppressor protein-tyrosine phosphatase DEP-1/ PTPRJ. Blood. 2012; 119(19):4499-511. DOI: 10.1182/blood-2011-02-336446. View

15.

Finkel T . Signal transduction by reactive oxygen species. J Cell Biol. 2011; 194(1):7-15. PMC: 3135394. DOI: 10.1083/jcb.201102095. View

16.

Naughton R, Quiney C, Turner S, Cotter T . Bcr-Abl-mediated redox regulation of the PI3K/AKT pathway. Leukemia. 2009; 23(8):1432-40. DOI: 10.1038/leu.2009.49. View

17.

Zhu P, Tong B, Wang R, Chen J, Foo S, Chong H . Nox4-dependent ROS modulation by amino endoperoxides to induce apoptosis in cancer cells. Cell Death Dis. 2013; 4:e552. PMC: 3615744. DOI: 10.1038/cddis.2013.68. View

18.

Zhang M, Brewer A, Schroder K, Santos C, Grieve D, Wang M . NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis. Proc Natl Acad Sci U S A. 2010; 107(42):18121-6. PMC: 2964252. DOI: 10.1073/pnas.1009700107. View

19.

Rajala H, Eldfors S, Kuusanmaki H, van Adrichem A, Olson T, Lagstrom S . Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood. 2013; 121(22):4541-50. PMC: 3668487. DOI: 10.1182/blood-2012-12-474577. View

20.

Crosas-Molist E, Bertran E, Sancho P, Lopez-Luque J, Fernando J, Sanchez A . The NADPH oxidase NOX4 inhibits hepatocyte proliferation and liver cancer progression. Free Radic Biol Med. 2014; 69:338-47. DOI: 10.1016/j.freeradbiomed.2014.01.040. View